Neunos develops a minimally invasive, implantable neuromodulation system for seizure suppression, positioned as a non-pharmaceutical treatment approach for epilepsy. The company frames its approach around closed-loop detection and intervention based on pathological brain-wave activity.

The platform is based on Intersectional Short Pulse (ISP) stimulation, designed to deliver time-locked “counter-wave” stimulation when seizure-like dynamics emerge. Neunos describes a mathematical detection-and-response model that operates continuously and autonomously, tailoring stimulation to the detected episode.

Primary deployment is framed for clinical use in people with epilepsy, with development milestones oriented toward pilot and pivotal studies and eventual CE-mark/FDA pathways. Neunos also signals exploratory work in select neuropsychiatric indications, while keeping epilepsy as the core clinical focus.